Ysios Capital is a biotechnology investment firm in Spain. Established in 2008, Ysios Capital has over € 200 million in resources under administration through its two assets: Ysios BioFund I (€65 M) and Ysios BioFund II Innvierte (€ 126M). They expect to make an incentive by giving capable entrepreneurs the assets and tools to make progress in changing intellectual capital and logical information into effective companies. Their group is composed of experienced professionals with broad experience in contributing and building healthcare and biotechnology businesses.
This venture capital gives private equity financing to early and middle stage healthcare and life science companies. They focus on the biotechnology industry, with a focus on therapeutics.
A biopharmaceutical company that develops nanotherapeutic treatments for ocular diseases and other eye related conditions
AM-Pharma is a biopharmaceutical company developing recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to treat patients with Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.
VarmX is a Netherlands-based biotechnology company manufacturing therapeutic proteins to restore blood clotting in bleeding patients.
BioClin Therapeutics is a San Ramon, California-based company.
Joel Jean Mairet
Managing Partner and Co - Founder
Executive Assistant & Corporate Communications, Office manager
Documentaries, videos and podcasts